Verastem, Inc. Form 8-K Filing

Verastem, Inc. announced the departure of its Chief Operating Officer, Matthew Ros, effective December 19, 2025. In connection with his separation, Mr. Ros will receive severance benefits including nine months of base salary continuation, continued health and dental plan coverage under COBRA for nine months (or until he becomes eligible for a new employer's plan), and a pro-rated bonus for the portion of the year he was employed. The separation agreement includes customary provisions regarding release of claims, non-disparagement, cooperation, and return of company property. The company also announced strategic leadership changes, with John Johnson appointed as chairman of the board and Michael Kauffman as president of development. These changes are intended to accelerate the company's next phase of growth. Additionally, Verastem Oncology reported that its RAMP 301 Phase 3 trial in recurrent LGSOC has completed additional patient enrollment, with topline data anticipated in mid-2027.